CVSI · CV Sciences, Inc.
$0.01
0.00 (-10.71%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company's financial operating results and accumulated deficit, amongst other factors, raise substantial doubt about the Company's ability to continue as a going concern. The Company will continue to work towards increasing revenue and operating cash flows to meet its future liquidity requirements. However, there can be no assurance that the Company will be successful in any capital-raising efforts that it may undertake, and the failure of the Company to raise additional capital could adversely affect its future operations and viability.”View the 10-Q filed Aug 13, 2026
Market Cap
$2.26M
Shares
225.83M
Volume · Oct 20
2.36M
Avg daily vol (3M)
542.99K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.01
Open$0.01
Day$0.01–0.01
52W close$0.01–0.09
Avg vol 30d551K
Short int14K · 0.0% float · 1.0d
Short vol42%
Last earningsAug 13, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Nov 13, 2026
Est · unconfirmed
· in 3 wks
filed Aug 13, 2026
call held Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$12.74M
Trailing 12 months
Net income (TTM)
−$2.01M
Trailing 12 months
Revenue growth YoY
-17.5%
Year over year
Operating margin
-7.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-23.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$248,000
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+11.3%
Year over year · more shares
Price change (1Y)
-75.0%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 13, 2026
Q2 FY26
TL;DR. CV Sciences reported Q2 2026 revenue of $3.0 million, down 17.5% year-over-year on a 14.9% decline in units sold, while gross margin compressed and adjusted EBITDA swung from a gain to a loss. The company cut operating expenses by 11.3% year-over-year and generated positive operating cash flow, launched the PlusHLTH.com e-commerce platform, and highlighted U.S. Senate approval of H.R. 6500 delaying restrictive hemp regulations.
Bullish
- + U.S. Senate approved H.R. 6500 delaying restrictive hemp-derived cannabinoid regulations
- + Generated positive operating cash flow of approximately $20,000 in Q2 2026
- + Maintained #1 selling hemp extract brand position in natural product retail channel
Bearish
- − Revenue declined 17.5% year-over-year to $3.0 million on a 14.9% drop in units sold
- − Adjusted EBITDA swung from a gain of $0.1 million in Q2 2025 to a loss of $0.1 million in Q2 2026
- − Gross margin compressed year-over-year to 48.6% from 50.9%
- − Operating loss widened to $0.3 million from $0.1 million year-over-year
- − GAAP net loss widened to $0.8 million from $0.3 million year-over-year
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−67%
below
Price vs 50-day avg
−39%
below
RSI (14)
36
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−33%
trailing
6-month return
−67%
trailing
YTD return
−83%
this year
Relative strength
−75%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Accumulating
+100% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.01% of float · ▲ +123.1% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
2 holders — near 3-yr high, broad support
Squeeze score
22
low risk · 0–100
Fundamentals
Revenue growth
−18%
Y/Y
Gross margin
34%
expanding
EPS growth
0%
Y/Y
Free cash flow
$-516.0K
Balance sheet
$1.4M
net debt
Quant / Vol
risk profile
Volatility
227%
annualized · 1-yr
Max drawdown
−89%
past year
ATR
21.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−67%
Bearish
Price vs 50-day avg
−39%
Bearish
RSI (14)
36
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Accumulating
+100% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.01% of float · ▲ +123.1% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
2 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $0
vs 200-day avg -67%
vs 50-day avg -39%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $0.1M | second quarter 2025 | — |
| Adjusted EBITDA loss non-GAAP | $0.1M | second quarter 2026 | — |
|
|
|||
| Net revenue from new products as a percentage | 44% | second quarter 2026 | — |
| New products launched since January 1, 2023 | 52 | second quarter 2026 | — |
| Units sold percentage change | 14.9% | second quarter 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CVSI
this stock
CV Sciences, Inc.
|
$2.26M | -83.3% | -17.9% | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$64.15B | +28.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$48.88B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$46.21B | +30.9% | +4.3% | 67.7 | 2.6% |
|
HLN
Haleon plc
|
$44.72B | +0.6% | — | — | 0.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
2
- % held
- 0.0%
- Net QoQ
- +100 sh
- Top holder
- MassMutual Private Wealth…
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CVSI | -30.6% | -33.3% | -66.7% | -20.6% | -83.3% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -29.4% | -32.8% | -74.8% | -21.5% | -96.1% |